Post-Market Clinical Study in COVID-19 Patients
Posted: 12 December Starpharma Holdings Limited announced that it has commenced recruitment in the UK for a post-market clinical study of its broad-spectrum antiviral barrier nasal spray, VIRALEZE, in patients with COVID-19, following receipt of the necessary regulatory…
Kynetyka’s DVTect technology secures Canadian patent
Posted: 9 December Kynetyka Technologies Pty Ltd, a privately held Melbourne-based medical device company, is pleased to announce that it has received a Notice of Acceptance in support of the Canadian patent, “A screening test for detection of…
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Posted: 8 December Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha, a first-in-class soluble LAG-3 protein, with…
Polygenic risk scores for cardiovascular diseases and type 2 diabetes
Posted: 8 December Genetic Technologies Limited, a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is delighted to announce the publication of a peer-reviewed paper describing the development and validation of the polygenic risk…
Imagion presents MagSense interim study results at breast cancer meeting
Posted: 8 December Imagion Biosystems Limited, a company dedicated to improving healthcare through the earlier detection of cancer, presented interim data from the Company’s ongoing Phase I study for its MagSense HER2 breast cancer imaging agent at the 2022…
Tessara Therapeutics and NETRI to collaborate on the development of next generation 3D brain-on-a-chip model
Posted: 5 December Tessara Therapeutics Pty Ltd and NETRI have established a collaboration to develop a family of next generation organ-on-chip models for neurological disease. The new models will combine Tessara’s RealBrain® 3D neural micro-tissues with NETRI’s NeoBentoTM…
IONIC Trial Progresses as Veyonda Passes Safety Milestone
Posted: 2 December Innovative Australian biotech Noxopharm Limited provides an update on the IONIC Investigator-initiated pilot Phase 1 trial of its lead oncology drug candidate Veyonda®. IONIC is exploring the potential of Veyonda to increase the activity of…
Melbourne lab new hub for exosome research, development and production
Posted: 2 December INOVIQ Limited has announced that it has transferred all research, development and manufacturing for EXO-NET to its Melbourne facility. The company has indicated that this ‘exosome core facility’ will allow INOVIQ to streamline its research…
Immutep Limited has signed a Clinical Trial Collaboration and Supply Agreement with Merck Group and Pfizer for a new Phase I clinical study in urothelial cancer patients called INSIGHT-005.
Posted: 29 November Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immuno therapies for cancer and autoimmune disease, is pleased to announce it has signed a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany…
Levelling up advanced manufacturing at RMIT
Posted: 29 November RMIT’s Advanced Manufacturing Precinct (AMP) is expanding to include 3 cutting-edge facilities that will deliver 21st century manufacturing. The new, expanded precinct will remain based at the City Campus site and accommodate the original AMP now known as…
U.S. Food and Drug Administration approves CSL’s HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
Posted: 24 November Global biotechnology leader CSL announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the…
Applications Open: CSIRO ON Prime
Posted: 23 November Closes: 17 February 2023 ON Prime is a free program designed to help research teams of two to five people take their projects to the next level through customer discovery activities and more. We work…
